As indicated by retrospective subgroup analysis from IMpower 150 study [11], NSCLC patients with EGFR mutation and TKI resistance derived progression-free survival (PFS) (9.7 vs. 6.1 months, HR,0.59) and OS (29.4 vs. 18.1 months, HR,0.6) benefits from combination therapy of atezolizumab, bevacizumab, and chemotherapy, compared with bevacizumab plus chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.